Research programme: NMDA receptor agonists - Tikvah
Latest Information Update: 16 Jul 2016
At a glance
- Originator Apkarian Technologies LLC; Therapade Technologies LLC
- Developer Tikvah Therapeutics
- Mechanism of Action Glycine NMDA-associated agonists; NMDA receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Anxiety disorders; Pain
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Pain in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Anxiety-disorders in USA (PO)
- 13 Feb 2007 Preclinical trials in Anxiety disorders in USA (PO)